Gene · 387893
KMT5A: lysine methyltransferase 5A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KMT5A: lysine methyltransferase 5A. Genes, record 387893. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/387893
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NQR1 | N-lysine methyltransferase KMT5A | 393 | 18 | Ensembl, GeneID, HGNC |
Source UniProt
Patents5
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants885
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KMT5A papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 22 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 8 | 2025 |
| ZIABC010411 | Initiation of DNA Replication in Mammalian Cells | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 7 | 2025 |
| ZIABC005599 | Tumor Suppressor Protein, p53 | 6 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 5 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 5 | 2025 |
| R35GM131858 | Interrogating Complex Methylome Network with Integrated Chemical Biology Tools | 5 | 2025 |
| T32CA009109 | Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies | 5 | 2025 |
1 to 10 of 885Source NIH's project files
See all 885 nih grantsPapers1,291
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reliability of Specific High-Intensity Interval Exercise Protocol for Judo Athletes. | Int J Sports Physiol Perform | 2026 | 42772724 | PubTator, text mining | PubMed |
| KMT5A maintains muscle stem cell quiescence through epigenetic regulation of Notch signaling. | iScience | 2026 | 42733840 | PubTator, text mining | PubMed |
| SETD8-mediated mono-methylation of YAP at K76 promotes K48-linked polyubiquitination and degradation to suppress colorectal cancer. | Cell Death Differ | 2026 | 42527521 | PubTator, text mining | PubMed |
| KMT5A-mediated methylation of IRF3 promotes tumor progression through immune suppression. | iScience | 2026 | 42495531 | PubTator, text mining | PubMed |
| Unraveling the Exosome-Derived ceRNA Network of Cartilage Injury in Kashin-Beck Disease Chondrocytes. | Biol Trace Elem Res | 2026 | 42406332 | PubTator, text mining | PubMed |
| Transcriptional Dysregulation of Histone Methyltransferase Genes and Chromosomal Instability Associated With Chronic Pesticide Exposure. | Environ Mol Mutagen | 2026 | 42318987 | PubTator, text mining | PubMed |
| Genomic characterization of uterine adenomatoid tumors reveals recurrent alterations in KMT5A and KMT2C. | Clin Epigenetics | 2026 | 42144646 | PubTator, text mining | PubMed |
| Inhibition of human histone lysine methyltransferases by a redox-labile S-adenosyl-L-homocysteine analog. | Sci Rep | 2026 | 42129275 | PubTator, text mining | PubMed |
| The reprogramming and function of H4K20me1 during early embryo development. | EMBO Rep | 2026 | 42020515 | PubTator, text mining | PubMed |
| SETD8 promotes ovarian clear cell carcinoma by epigenetically activating RNA metabolism genes via H4K20me1. | Sci Rep | 2026 | 41986648 | PubTator, text mining | PubMed |
1 to 10 of 1,291
See all 1,291 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/387893
GET https://conductscience.org/api/genes/v1/387893/grants?page=2